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Abstract Understanding how our use of antimicrobial drugs shapes future levels of drug
resistance is crucial. Recently, there has been debate over whether an aggressive (i.e., high dose) or
more moderate (i.e., lower dose) treatment of individuals will most limit the emergence and spread
of resistant bacteria. In this study, we demonstrate how one can understand and resolve these
apparently contradictory conclusions. We show that a key determinant of which treatment strategy
will perform best at the individual level is the extent of effective competition between resistant and
sensitive pathogens within a host. We extend our analysis to the community level, exploring the
spectrum between strict inter-strain competition and strain independence. From this perspective as
well, we find that the magnitude of effective competition between resistant and sensitive strains
determines whether an aggressive approach or moderate approach minimizes the burden of
resistance in the population.
DOI: 10.7554/eLife.10559.001
Introduction
The growing crisis of resistance to antimicrobial drugs has captured the attention of the global public
health community as the harrowing reality of the loss of previously effective medicines combined with
slow discovery of new agents threatens a post-antibiotic era of untreatable infectious diseases.
Although the quality and completeness of surveillance is variable, current data are consistent with rising
levels of resistance; this worrisome trend is not restricted to particular pathogens or specific
geographic settings (WHO, 2014). While an accurate assessment of the current health and economic
losses attributable to antibiotic resistance is elusive, the estimated numbers, ranging up to 2 million
serious infections, 23,000 deaths, and 35 billion dollars in the United States alone, are staggering (CDC,
2013). Similar numbers of deaths have been attributed to antibiotic-resistant infections in Europe
(O’Neill, 2014). Most recently, a projection of 10 million deaths and 100 trillion dollars in economic
losses attributable to antimicrobial-resistant infections by 2050 has been circulated (O’Neill, 2014).
Given that antimicrobial treatment cures infections while simultaneously selecting for antimicrobial
resistance, it is crucial to understand how alternative treatment strategies affect the probability of
resistance. The conventional wisdom guiding the rapidity and dosing of drugs, often attributed to Paul
Ehrlich, (Ehrlich, 1913) is that early and aggressive use of antimicrobial agents is most effective for
optimizing cure and minimizing the risk of resistance (Levin et al., 1999). Recently, there has been some
debate as to the universality of the claim that these aggressive approaches are optimal for minimizing
the risk of resistance, with some researchers suggesting that more moderate approaches may perform
better (Read et al., 2011) and others defending the standard approach (Ankomah and Levin, 2014).
A central rationale for an aggressive approach is that early high dose treatment will most rapidly
reduce the size of the microbial population from which drug-resistant isolates appear and thus
minimize the probability of the emergence of resistance during treatment (Bonhoeffer et al., 1997;
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Knudsen et al., 2003; Wiuff et al., 2003; Tam et al., 2005, 2007; D’Agata et al., 2007; Ankomah
and Levin, 2014; Kim et al., 2014). In contrast, the rationale for a more moderate approach is that
higher doses of antibiotics impose stronger selective pressure which drives a more rapid emergence
of resistance (Read and Huijben, 2009; Read et al., 2011; Kouyos et al., 2014), and that rapid
suppression of drug-susceptible isolates may allow for competitive release of existing drug-resistant
isolates (de Roode et al., 2004; Wargo et al., 2007; Huijben et al., 2010; Pena-Miller et al., 2013;
Pollitt et al., 2014). Recently, Kouyos et al. (2014) summarized the relevant, albeit limited, empirical
evidence about dosing and risk of resistance, and described a ‘conceptual curve’ relating the strength
of selection to the expected rate of resistance emergence, highlighting theoretical conditions under
which aggressive and moderate approaches may be preferred.
How one formulates the question about optimal antimicrobial dosing strategies to minimize
resistance will depend on one’s perspective. For example, a clinician will likely be most concerned with
identifying the dosing regimen that produces the best health outcome for the patient (i.e., highest
probability of cure accounting for toxicities and the risk of resistance). A public health practitioner will
likely seek to identify which treatment practices produce the greatest health gains while minimizing
the long-term levels of resistance in the community. The recent debate over aggressive and moderate
approaches has mainly been centered on identifying an optimal strategy for the treatment of
individual hosts to minimize the probability of resistance. However, the emergence and subsequent
transmission of resistance in the population may be of even greater concern. From a theoretical
perspective, optimal dosing strategies for the prevention of resistance in individuals are not
necessarily optimal for limiting resistance at the population level (Lipsitch and Samore, 2002; Mills
et al., 2013).
eLife digest Antibiotics are chemical compounds used to treat bacterial infections. The
discovery of antibiotics, starting with penicillin in 1929, revolutionized medicine, making it possible to
cure or prevent life-threatening infections such as tetanus and pneumonia. However, many bacteria
have become resistant to one or more antibiotics and so can no longer be killed by these drugs.
The emergence of antibiotic resistance reflects an evolutionary process that occurs during
antibiotic treatment. While the antibiotic will kill most bacteria, some bacteria may naturally have a
feature or genetic mutation that allows them to survive in the presence of the antibiotic. These
bacteria then reproduce and pass on their resistant traits, eventually leading to the emergence of a
new antibiotic-resistant strain of bacteria. Once a resistant strain exists it may be able to spread from
one person to another.
There is conflicting evidence about how best to prevent antibiotic-resistant bacteria from evolving
and spreading. The results of some experiments suggest that treating bacteria with large doses of
antibiotics early in an infection is the most effective way to optimize treatment and minimize the risk
of an antibiotic-resistant strain developing. However, other studies suggest that exposing bacteria to
high levels of antibiotics more efficiently selects for resistance; in this case a more moderate
approach should be used when treating bacterial infections.
Here, Colijn and Cohen present a mathematical model that suggests that the natural competition
between the antibiotic-resistant and antibiotic-sensitive strains of bacteria influence which treatment
strategy should be taken. Strains were modeled both within individual hosts and spreading in a
community of individuals. In the models, aggressive antibiotic treatment is most effective (in that it
minimizes antibiotic resistance) when the antibiotic-resistant strain either does not experience strong
competition from the non-resistant strains of bacteria or is not fit enough to be a good competitor.
However, a more moderate treatment is appropriate when the two strains are competing and the
antibiotic-resistant strain is a fit competitor. Competition may mean that moderate treatment is best
to avoid resistance at the community level, even in situations when aggressive treatment is likely best
for individuals.
Two important future challenges are to better understand the diversity of strains in bacterial
infections, and to develop tools to measure to what extent strains are effectively competing with
each other.
DOI: 10.7554/eLife.10559.002
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Here, we provide a modeling framework that unifies the individual-level and population-level
perspectives and provides additional insight into the debate about aggressive and moderate
approaches for antimicrobial treatment. We demonstrate that the extent of effective competition
between drug-susceptible and drug-resistant isolates is a key determinant of whether an aggressive
approach is better (in terms of resistance prevention) than a moderate approach for hosts being
treated for disease. Most importantly, we find that even within a model that allows for very strong
competition, different realistic combinations of parameter values can support the aggressive or
moderate approach as optimal. We illustrate how it is possible that models can support two such
different conclusions by carefully considering the dominant interactions between the strains. We
extend our analysis to the population level, exploring a spectrum of inter-strain interactions ranging
from strict competition to independence. We find that the same framework explains why either
aggressive or moderate treatment approaches can minimize resistance.
Materials and methods
Within-host model
We describe two populations of bacteria within a single host using a model based on Ankomah and
Levin (2014). The model includes both wild-type (drug-sensitive; DS) bacteria and drug-resistant (DR)
bacteria which arise by some presumably rare mechanism from the drug-sensitive type. This
mechanism could be single-point mutation, acquisition of resistance genes through horizontal gene
transfer, or another mechanism (Lipsitch and Samore, 2002; zur Wiesch et al., 2011). While we do
not explictly model these differences, we note that the mechanisms of resistance and their
probabilities affect the relative importance of de novo resistance compared to pre-existing resistance
circulating in a population (Lipsitch and Samore, 2002). In our model, each strain initiates an immune
response which follows density-dependent kinetics. Bacteria grow in a resource-dependent manner
and have a death rate which increases under higher antibiotic concentrations. Antibiotics enter the
system and degrade at a constant rate. The DR strain, by definition, has a higher minimum inhibitory
concentration (MIC) than the DS strain and is assumed to have a slower growth rate reflecting fitness
costs associated with mutation or acquisition of resistance genes. The phrase ‘minimum inhibitory
concentration’ parallels the language in Ankomah and Levin (2014); the MIC is the value of antibiotic
A at which the growth rate with the drug is half its baseline value (when A = 0). The strain interactions
in the model are complex: strains compete for resources, and each strain can suppress the other by
triggering a host immune response. Thus, we expect the strains to be under fairly strong competition.
However, the DS strain also benefits the DR strain as DR is generated from the DS population through
acquired resistance.
The equations are:
dBs
dt
=GsBs − kpPBs − kiIBs − μBs
dBr
dt
=GrBr − kpPBr − kiIBr + μBs
dI
dt
= αI
Bs +Br
Bs +Br + σi
− uiI
dP
dt
= ηðPmax −PÞ Bs +BrBs +Br + σp − γP
dR
dt
=wðCR −RÞ− eðGsBs +GrBrÞ
dA
dt
=Ain − ðd+wÞA:
(1)
The variables are the densities of DS and DR bacteria (Bs, Br in cells/ml) and the adaptive and innate
immune cells (I, P in cells/ml), and the concentration of the resource R (μmg/ml) and the antibiotic A
(μmg/ml). Bacterial growth is resource dependent (Ankomah and Levin, 2014) with growth rate
λs =Λs Rk +R and similarly for λr, where Λs and Λr are the maximum growth rates of the two strains when
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the resource is not limiting. The net growth rate Gs is Gs = λs − (us + δs(A)) and Gr = λr − (ur + δr(A)),
capturing death and the bactericidal effect of the antibiotic. We adopt the assumption that
recruitment of activated effector cells of the innate system (P) is dependent on the density of the
pathogen population (Bs + Br) and σp > 0 is a saturation constant. Similarly, we assume that the
expansion of specific adaptive immune response I is dependent upon the density of the pathogen
population, the maximal expansion rate α and σi, the pathogen density at which the increase in the
adaptive immune response is half maximal. The resource is replenished at rate wCR and depleted at
rate wR. In our baseline results we assume, as in previous work (Ankomah and Levin, 2014), that it is
the net growth Gs and Gr that determine the extent of the depletion of resources. This means that if
the net growth is negative, lysis of cells can replenish the resource. We assess the sensitivity of our
findings to this assumption in Appendix 1 and find that the model’s inter-strain dynamics and their
dependence on the parameters are unaltered when the lysis effect is removed (in which case the
resource equation in (1) reads dR/dt = w(CR − R) − e(ΛsBs + ΛrBr)). To incorporate the possibility of
stochastic die-off of the DR population when its density is very low, the growth rate is 0 when the
density is less than 30 cells/ml. Not allowing for stochastic die-off might allow resistant strains to enjoy
an unrealistic advantage in the model due to its deterministic nature. Here, 30 cells/ml is
approximately 10−8 times the maximum bacterial load, though this varies with the parameter choice.
Antibiotic concentration A speeds the death of bacteria according to a saturating mechanism
δsðAÞ= λs A=MsA=Ms +1, and similarly for R, where Ms and Mr are the minimum inhibiting concentrations of
antibiotic for the DS and DR strains, respectively. A is introduced through dosage Ain and is removed
at rate d + w (Ankomah and Levin, 2014).
To explore these complex interactions, we drew 60,000 sets of parameters from ranges containing
the values used previously (Ankomah and Levin, 2014) (see Table 1), spanning a range of strengths of
the immune system (ki, kp, η, α), relative overall fitness of the DR strain (Λr,Mr), pre-existing DR bacilli,
the growth rate of the DS strain (Λs), and the mutation parameter μ. Each parameter was chosen
uniformly at random from the ranges given in Table 1. All were held fixed, and the model was
simulated under multiple dosages. This gave us an understanding of how treatment affected
resistance at each set of parameters. We captured the relationship between increasing Ain and the
maximum and total (integrated over time in the simulations) DR at each randomly drawn set of
parameters.
We determined whether ‘aggressive’ or ‘moderate’ therapy was the best approach according to
which one minimized the overall (maximum and total) levels of resistance. If treatment is negatively
correlated with resistance, then more treatment results in less resistance and an aggressive
approach is best. Conversely, if the correlation is positive, then treatment drives increases in
resistance, and a moderate approach is best (from a resistance standpoint). Accordingly,
parameter sets in which resistance levels were negatively (S < −0.7) or positively (S > 0.7)
correlated with antibiotic dosage as determined by the Spearman correlation S were classed as
‘aggressive is best’ or ‘moderate is best’; other results were classed as neutral. We removed
parameter sets in which treatment does not succeed to avoid unfair inclusion of those parameter
sets in which the long-term selective pressure of unsuccessful treatment drives resistance. In
the main analyses, we assume that the threshold for successful treatment is defined as causing a
>80% reduction in the maximum DS population; in sensitivity analyses, we vary this threshold
and provide results from the full set of simulations in which such a threshold is not imposed
(see Appendix 1).
Between-host model
To explore a wide range of inter-strain interactions at the population level, we developed a model
with four host compartments: susceptible, infected with DS (X), infected with DR (Y) and dually
infected (D). We envision a continuum of inter-strain interactions that in principle describe co-
circulating pathogens. At one of the continuum, we posit that distinct pathogens may be entirely
independent of each other, not interacting directly or indirectly (e.g., through immune modulation or
resource competition). In this case, infection with one strain does not affect infection or recovery with
the other strain. At the other end of the continuum, very similar strains of the same pathogen are likely
to be competing for hosts. Figure 1 illustrates two models, one with strict competition and one with
independence.
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We have previously described ‘neutral null’ models (Lipsitch et al., 2009), in which biologically
indistinguishable strains have sensible dynamics in models (i.e., outcomes do not depend on which
strain a host has). Our model spans this continuum, which is parameterized by a ‘similarity coefficient’
c. When c = 1 the strains are highly similar and neutral in the sense of Lipsitch et al. (2009) if they are
identical. When c = 0, the two strains act independently; infection with one does not affect the spread
of the other. See Appendix 1 for more details and a proof of these statements.
The model equations are:
Table 1. Parameters and ranges
Symbol Description Range Unit
Within-host model
Λs Max growth rate (DS) 0.4–0.8 hr−1
Λr Max growth rate (DR) (0.6–1) × Λs hr−1
k Hill coeffient in bacterial growth 0.5–50.5 μg/ml
us, ur Death rates DS, DR 0.2 hr
−1
mS MIC (DS) 1 μg/ml
mR MIC (DR) 1–8 μg/ml
kp Rate of innate immune clearance 10
−7 − 10−5 hr−1
ki Rate of adaptive immune clearance 10
−5 − 10−3 hr−1
μ Rate of DR mutation 5 × 10−9 − 5 × 10−7 #/division
α Recruitment of adaptive immunity 0.002–0.02 hr−1
σi, σp Hill parameter in I, P dynamics 1000, 10,000 cells/ml
ui Loss rate of I 5 × 10−5 − 5 × 10−4 hr−1
γ Loss rate of P 5 × 10−4 − 5 × 10−3 hr−1
η Recruitment of innate immunity 10−5 − 9 × 10−4 hr−1
w Washout rate 0.2 hr−1
CR Resource reservoir concentration 300–700 μg/ml
e Use of resource per unit growth 5 × 10−7 μg/cell
Ain Antibiotic treatment 0–2.5 μg/(ml × 24 hr)
d Loss rate of antibiotic 0.1 hr−1
Between-host model
βx Transmission parameter (DS) 1–4 months
−1
βy Transmission parameter (DR) 1 − βx months−1
κ Partial immunity coefficient 1 none
κt Treatment protection from DS 1 − 0.3T none
c Similarity coefficient 0–1 none
u DS clearance without treatment 13 βx −
2
3 βx months
−1
uy DR clearance βy /R01 − βy months−1
T Intensity of treatment 0–1 none
r Release of DS through treatment 0–0.1 months−1
umax Max clearance DS under treatment 1.05 βx months
−1
Ranges are indicated with a − separating lower and upper values. Where a single value is given the parameter was
fixed. Within-host parameter ranges contain the values used in Ankomah and Levin (2014). The relative growth of
the resistant and sensitive strains (without treatment) can be modified either through k or Λ. We have chosen to vary
the Λ parameters as the effect on relative fitness is linear. In the between-host model the value of u was chosen such
that the DS strain has a basic reproductive number in Bonhoeffer et al. (1997) and Ankomah and Levin (2014).
Similarly, uy was chosen so that R02 ranges from 1 to R01, to ensure that the DR strain has a smaller maximum growth
rate than the DS strain.
DOI: 10.7554/eLife.10559.009
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dX
dt
=FxS− κFyX +
1
2
κtcFxD− uxX + ð1− cÞuyD− ðμ+ TrÞX
dY
dt
=FyS− κtκFxY +
1
2
κtcFyD− uyY + ð1− cÞuxD+12 TrD+ ðμ+ TrÞX
dD
dt
= κFyX + κtκFxY −
1
2
κtc

Fx +Fy

D− ð1− cÞux + uyD− 12 TrD−
1
2
c

ux + uy

D
ux = u+ ðumax − uÞT ;     Fx = βxX +

1−
1
2
c

D;     Fy = βyY +

1−
1
2
c

D:
(2)
In this model, hosts may become infected with both strains and enter the dually infected class (D);
the chance of this may be reduced by cross-immunity, which we assume is symmetric between
resistant and sensitive strains (κ). In models where dual infection cannot occur, there is an implicit
assumption of very strong competition between strains. Dually infected individuals may also be again
re-infected with a single strain (Lipsitch et al., 2009). Clearance terms (with recovery ux and uy) are
modulated with the similarity coefficient, c, to ensure that the model has independent interactions
when c = 0 and neutral null dynamics when c = 1 (see Appendix 1). Transmission rates are βx and βy,
recovery rates are ux and uy, and we assume that over the time frame of the simulation the population
does not change; we scale it to 1 so that S = 1 − X − Y − D. The forces of infection Fx and Fy contain a
contribution from both singly and dually infected hosts such that when the strains are different, dually
infected hosts contribute as much as singly infected ones, and when they are very similar, each strain
contributes half what a singly infected host would (Lipsitch et al., 2009). Treatment T ranges from 0 to
1 (where the DS strain is eliminated) and has several effects. Primarily, it cures the sensitive strain by
reducing its duration of infection 1/ux. Individuals with a resistant strain (Y) who are given treatment
are partially protected (κt) from re-infection with the sensitive strain. Dually infected individuals given
treatment have the drug-sensitive portion of their infection cured at an increased rate ux due to
treatment, but their resistant infection is not cured.
To capture the risk of releasing small sub-populations of resistant bacilli within such hosts, we include
a parameter r which is a small rate at which resistance is uncovered by treatment. This parameter links
the in-host and between-host models: in circumstances in which strong treatment drives increases in
resistance, r would be high (approaching the treatment rate ux of the sensitive strain).
We use a range of parameters such that the basic reproductive numbers (β/u) of the strains, R01
(DS) and R02 (DR), are greater than 1, with R02 < R01 (Table 1). We draw parameters randomly and
increase the treatment T. We explore the relationship between the strength of treatment and the
long-term and maximum level of resistance. We classify the resulting optimal strategy as aggressive if
the Spearman correlation is less than −0.7 and moderate if it is larger than 0.7.
The between-host model admits three possible steady states (equilibria): a disease-free equilibrium
(X = Y = D = 0 stable when R01 and R02 are both less than 1), a resistance-only steady state (X = D = 0,
Y = 1 − uy/βy), and a steady state with X, Y, and D positive whose explicit form is not available. If there
were no acquisition of resistance (μ = 0) and no ‘competitive release’ term (transition from X to Y),
there would be an additional equilibrium with Y = D = 0 and X = 1 − ux/βx. We carried out an invasion
analysis to determine the point at which the resistance-only equilibrium loses local stability as βx
increases. When the two strains are independent, X should be prevalent if and only if R01 ≥ 1. But if
they are not, the values of the strain Y parameters (and its prevalence) affect the prevalence of X. We
performed the invasion analysis as follows: we computed the Jacobian of model (2) and evaluated it at
the resistance-only steady state for a given set of parameters including βy. We used matlab’s nonlinear
solver, fsolve, to determine the value of βx at which the resistance-only steady state loses stability. We
repeated this for a range of values of βy to produce the colored lines in Figure 5C.
Determining the role of parameters in defining whether treatment
increases or decreases resistance
We took several approaches to understand how the parameters of each model relate to whether
aggressive or moderate treatment minimizes resistance. The most direct approach is simply to choose
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a set of parameters, vary the dosage, and examine how resistance changes (Figure 2). Naturally, the
result depends strongly on the parameter choice. We also vary one parameter at a time, keeping
others fixed, and examine the trajectories (Appendix figures 2, 3). The next approach is to examine,
over all simulations simultaneously, how the outcome depends on each parameter by stratifying the
outcomes (Figure 3). Using heatmaps or scatter plots, it is also possible to explore how pairs of
parameters determine an outcome (Figure 4). We take the same approach in the between-host
model, with Figure 5 showing demonstrative trajectories under varying treatment strength, Appendix
figure 4 showing a sensitivity analysis varying one parameter at a time, and Figures 6, 7 showing the
stratified dependence of the outcome on single and paired parameters while other parameters are
allowed to vary.
Figure 1. Models at the two ends of the competition independence spectrum (between hosts). In the competing model (top row), decreasing the DS
strain (X) paves the way for an increase in resistance (Y) by removing the DR strain’s competitor, despite the fact that decreasing DS also removes a source
of resistance. The bifurcation analysis illustrates competitive exclusion: whichever strain has the higher R0 excludes the other. In both cases, some
resistance is present when the sensitive strain is present, due to acquisition of resistance, for example, through mutation. Consequently, the ‘1-only’ region
of the plot has some strain 2 at very low prevalence. In contrast, if the strains are not competing (bottom row), including not competing for hosts, hosts
must be able to harbor both infections (duals, D). In this case, reducing DS reduces DR by reducing a source of resistance. The bifurcation plot where
strains are independent illustrates that strain 1 is present if R01 > 1, strain 2 is present if R02 > 1 and both are present if they are both >1. Our between-host
model incorporates competition and independence, parameterized by a ‘similarity coefficient’ that smoothly moves from one to the other (see Appendix
1 for details).
DOI: 10.7554/eLife.10559.010
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However, we cannot expect any one or two parameters to entirely determine which approach
minimizes resistance. We used discriminant analysis of principal components (DAPC, in the adegenet
package in R [Jombart and Ahmed, 2011]) to systematically identify which parameters contribute to
each outcome (Jombart et al., 2010). DAPC is related to principal component analysis (PCA) but
instead of finding combinations of parameters to account for the variability in data (as PCA does),
DAPC finds combinations of parameters that best account for variability between groups. Here, we
used whether aggressive or moderate treatment minimizes resistance to define the groups
(aggressive, neutral or moderate as above) and used DAPC to find combinations of parameters
that separate these groups from each other.
Results
The best policy for reducing the amount of resistance in both models can be either aggressive or
moderate despite the fact that both models capture potentially strong competition and the
acquisition of de novo resistance. The choice of best approach depends on the combined effect of the
complex set of inter-strain interactions, and typically, one of these approaches is the clear winner (see
Appendix figure 5).
Within-host model
Figure 2 illustrates how treatment dosage may affect the level of resistance in the in-host model.
Whether treatment increases or decreases resistance over the course of infection depends on many of
Figure 2. How treatment changes the trajectory of the in-host model. Parameters are (A) Λs = 0.5, Λr = 0.45,mR = 2.8 and (B) Λs = 0.6, Λr = 0.53,mR = 3.4.
Other parameters are k = 48, kp = 2.2e−6, ki = 7.2e−4, μ = 4e−7, α = 0.018, σi = 1000, σp = 10000, γp = 0.001, and the remainder are as in Table 1.
DOI: 10.7554/eLife.10559.003
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the parameters in the model. We performed a sensitivity analysis to determine how the relationship
between resistance and dosage changes with each parameter when the others are held fixed
(Appendix figures 2, 3). We found that the relationship is relatively robust to variation in each
parameter alone, but that small changes in several parameters can have a radical effect. In Appendix
figure 2, increasing the dosage does not increase resistance and this result is fairly robust to variation
in each parameter alone; Appendix figure 3 shows the contrasting robust scenario (increased dosage
increases resistance). The difference is that the baseline parameters in Appendix figure 3 have
somewhat higher growth Λs and Λr of both strains and the resistant strain has a higher MIC.
No single parameter determines whether aggressive or moderate treatment minimizes resistance. A
relatively small change in several parameters can shift the model from one mode to the other. We
separated parameter combinations in which aggressive vs moderate treatment minimizes resistance using
a principled approach (DAPC;Appendix figure 6). We found that a linear combination of parameters (one
‘principle component’) captures almost all of the difference between the three groups (aggressive
minimizes DR, moderate minimizes DR, or neutral, i.e., in between). The ‘loadings’ (e.g., coefficients) of the
parameters in this linear combination correspond to the relative importance of the parameters in
determining whether aggressive or moderate treatment minimizes resistance. The number of pre-existing
resistant cells affects the outcome (coefficient 0.79). When pre-existing numbers are low (<10), parameters
which lead to a ‘moderate’ policy to be best include higher growth rate of the DR and DS strains
(ΛR, 1.4 and ΛS, 0.92), lower immune parameters kp and η (−0.74; −0.66) and a higher MIC of the DR strain
(mR; 0.34). Other parameters had loadings less than 0.1 and did not contribute much to the classification.
In other words, we find that an aggressive approach is preferred when the immune system is
relatively strong (higher values of immune parameters kp, η), and when the DR strain has a relatively
low growth rate (ΛR) and low MIC (mr). Conversely, if there is pre-existing resistance, the immune
system is weaker, and/or the growth rate or MIC higher, a moderate approach minimizes resistance.
Pre-existing populations of DR pathogens (i.e., resistance that appears prior to exposure to
treatment) favor a moderate approach, since there is no possibility that a hard-and-fast approach will
clear the infection before resistance can arise.
Figure 3 illustrates how the best policy relates to individual model parameters, and Appendix
figures 7, 8 show the distributions of individual parameters where treatment increases or decreases
Figure 3. Frequency of best policies over key parameters. An aggressive policy (dark blue) is deemed best if the Spearman correlation S between
treatment and resistance is S < −0.7, moderate (light blue) is deemed best if S > 0.7 and the classification is neutral (medium blue) otherwise. When the DR
strain has a lower growth rate (LamR), an aggressive policy is more likely best because more of the DR strain’s population arises through resistance
acquisition from the DS population. In this case, reducing the DS strain also reduces DR. Conversely, when ΛR (LamR) is high the DR strain is a more robust
competitor and a moderate policy is more frequently best. Similarly, when the DR strain has a low MIC (mR), it is a less robust competitor. In this case, an
aggressive policy is more frequently best than when mR is high (second panel). The third panel shows that when the immune system is strong (high kp), an
aggressive policy is more frequently best, because again more of the DR population increases are driven by acquisition from DS, due to immune
suppression of DR growth. A plot with η on the horizontal axis is very similar to this one. Finally, the right plot shows that when the DS growth rate (LamS) is
low, an aggressive strategy is more often best to minimize resistance; this depends on the ability of therapy to prevent the emergence of resistance.
DOI: 10.7554/eLife.10559.004
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resistance. No single parameter determines which policy is best; rather, the outcome depends on the
combined effects of a set of complex interactions. This means that from a location in parameter space
where aggressive therapy minimizes resistance, a relatively small change in several parameters (e.g., a
slight decrease in kp, increase in mR and increase in Λr) can result in a moderate policy being best.
Figure 4 shows the best policies for key pairs of parameters whose values combine to influence
whether an aggressive or moderate policy minimizes resistance. These figures reveal a few intuitive
trade-offs: a higher DR growth rate (ΛR) generally leads to a moderate policy being best (light blue;
positive correlation between treatment and DR), but this can be offset with a strong immune system
keeping both strains in check (high η or high kp). A higher DR growth rate or a higher MIC (mR) make
the DR strain a robust competitor and also consequently favors a moderate policy. Interestingly,
while the mutation rate affects the overall numbers of DR bacteria (particularly in cases when they
are not present initially), it does not have a strong effect on the relationship between treatment and
total resistance.
If resistant cells are present initially, then they do not need to emerge by (rare) mutation or
acquisition mechanisms from the sensitive strain. This simple observation has consequences for our
analysis; a ‘moderate is best’, or neutral conclusion is much more likely with pre-existing resistance,
keeping everything else the same. When there is no pre-existing resistance, the DR strain must have a
higher MIC, higher growth rate and face a weaker immune system in order to be a robust competitor
than it does when it is present initially. Appendix figure 1 shows the heatmaps as in Figure 4 but
stratified according to whether there is pre-existing resistance.
Figure 4. Heatmaps illustrating how best policies depend on key combinations of parameters. Color indicates the policy that minimizes resistance. Yellow:
aggressive; green: neutral; blue: moderate. When the growth rate ΛR (LamR) is high, a moderate policy is more frequently best, but a strong immune
system (high kp) can compensate by reducing DR growth. When the DR strain is a strong competitor, a moderate policy is frequently best; this can be
achieved by either a high ΛR or a high DR MIC (mR) (top left). Either a high kp or a high η can compensate (bottom right), reducing the growth potential of
the DR strain and leading to either a neutral outcome or an aggressive policy being best.
DOI: 10.7554/eLife.10559.005
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To understand which policy minimizes resistance, one must be able to characterize the net effect
that the presence of one strain has on the other strain. There is strong opportunity for competition
between strains encoded in the model; competition plays out through shared resources which may be
limiting as well as through the triggering of an immune response that suppresses both strains equally.
Both of these effects occur when bacterial populations are large. However, the initial appearance of
resistance also depends critically on the presence of drug-sensitive organisms. Altering both the
Figure 5. Trajectories of the between-host model under varying treatment. Treatment is introduced at 5 years. (Left) Parameters are βx = 1.5, βy = 1.04,
c = 0.05, r = 0, μ = 0.001. (Middle) Parameters are βx = 2, βy = 1.1, c = 0.3, r = 0.05, μ = 0.0001. (Right) Invasion analysis (bifurcation) plot. The plot shows
regions of stability of the disease-free equilibrium (both R0 values less than one), the DR-only equilibrium (top left region), and the equilibrium with both
(primarily DS, with low-level DR due to acquisition). The diagonal lines show the boundary at which the DR-only equilibrium loses stability. Lines move to
the right as the similarity coefficient increases from 0 (light blue vertical line) to 1 (pink). When it reaches 1, the line is R01 = R02.
DOI: 10.7554/eLife.10559.006
Figure 6. Best policy over parameters in the population-level model. Light blue corresponds to Spearman correlation greater than 0.7, dark corresponds
to less than −0.7 and mid-range blue corresponds to all values in between. An aggressive policy is best when the DR strain is relatively unfit (low R0 value;
left panel). When the acquisition rate is high, treatment-driven reductions in DS decrease the DR prevalence (second panel). When the two strains are
more independent (low similarity coefficient), competition is reduced, so that reductions in the DS strain do not much benefit the DR strain, leading to the
aggressive policy being preferred (third panel). When R01 is high, a moderate outcome results, because inter-strain competition is more effective. Vertical
axes (‘count’) are the fraction of simulations in each category.
DOI: 10.7554/eLife.10559.007
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strength of competition and the dependence of the DR strain on the DS progenitor population
determines whether or not such competition is effective. In particular, effective competition naturally
requires a DR strain that has the capacity to be a robust competitor to the DS progenitor. This can be
achieved in two ways: it can maintain a strong growth capacity in the presence of antibiotic treatment
or immune pressure, or it can face an immune system that is not particularly strong. Our exploration of
the parameter space uncovered both of these mechanisms. These findings are not an artifact of the
model structure, and indeed they will likely occur in any model that includes de novo appearance of
resistant strains by mutation or acquisition of resistance determinants by drug-sensitive organisms,
and where resistant strains can then compete for resources with their drug-sensitive cousins.
Effective competition can be described as the net extent to which a decrease in one strain benefits
the other. This should capture both direct and indirect effects. Quantifying effective competition is
challenging because either strain may affect the other over short or long time frames and because
different ways to decrease one strain have different effects. From the second equation of (1), the direct
effect of a decrease in Bs on the immediate growth of the resistant strain is simply the change in the
acquisition term (μBs). If the other terms are small, this term can make the difference between net
growth and net decline of resistant cells. The indirect effects are more difficult to determine; a decrease
in Bs will mean more available resource and reduced recruitment of immune cells which will have onward
effects. Wemade a step towards quantifying effective competition as follows. We numerically solved the
system, obtaining values of each variable through time. We decreased Bs and computed the predicted
value of Br two time steps later, using Euler’s method, the derivatives in (1) and the time steps defined
by the adaptive ODE solver. We did this (separately) at each time point and averaged the fractional
change in Br due to a 5% change in Bs over the portion of the trajectory where Bs > 105. We do this only
in the untreated case, for each value of the parameters we sampled. This captures only the immediate
indirect effects (occurring in the next two small time steps) and the intervention we made (reducing Bs
when dosage is 0) is not the same as treatment. Nevertheless, this formulation of effective competition is
a good predictor of whether treatment, when added, increases resistance. We used it to classify whether
treatment would increase or decrease resistance, and found that the classification worked well, with an
area under the receiver–operator characteristic curve (AUC) of 0.94 (the theoretical maximum is 1, and a
classifier that guesses randomly has AUC of 0.5). See Appendix figure 10.
Between-host model
Figure 5 illustrates the behavior of the between-host model at two demonstrative parameter sets, one
illustrating resistance decreasing with treatment due to the dominant effect of acquisition of DR from
Figure 7. Best policy over parameter combinations in the population-level model. A moderate-is-best (blue) outcome occurs when R01 and the similarity
coefficient are high, because the strains are competing (left panel). When the DR strain is relatively unfit (low R02), an aggressive policy is likely best (second
and third panels); we restricted R02 to be lower for the DR strain than the DS one. A high rate of acquisition can counter-balance a low R02 (second panel).
When the strains are more independent (low similarity coefficient), an aggressive policy is more often best even over a much wider range of R02 (third panel).
DOI: 10.7554/eLife.10559.008
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the DS strain, and the other illustrating resistance increasing with treatment as a result of inter-strain
competition. Appendix figure 4 shows the relationship between resistance and strength of treatment
and its sensitivity to variation in single parameters. No one parameter defines whether treatment
increases or decreases resistance.
The model has the possibility of three distinct steady states (equilibria): no disease, both DS and
DR present, and only the DR strain present. If there were no acquisition of resistance, there would also
be the possibility of an equilibrium with only the DS strain. Figure 5 shows that the stability region of
the DR-only equilibrium changes as the similarity coefficient increases. When c = 0, the DR-only
equilibrium is invaded by the DS strain as soon as R01 > 1 (vertical blue line). However, when the
strains are more similar, R01 must be higher in order to invade, and when c = 1, there is no equilibrium
DS prevalence unless R01 ≥ R02.
Appendix figure 9, Figures 6, 7 illustrate how the best policy depends on the fitness of the DR
strain and the other parameters. Treatment decreases resistance when the R0 values of both strains
are relatively low, the rate of acquisition of resistance is high and the similarity coefficient is low. We
find that the parameter groups where aggressive therapy minimizes resistance are well separated by
those where moderate therapy is best, by a single DAPC function (Appendix figure 6). Here, the
strongest driver of a moderate policy being best is a high similarity coefficient (c, coefficient 0.93).
High R02 and R01 (coefficients 1.01, 0.65) contribute, as does a low acquisition rate (coefficient −0.56).
Somewhat surprisingly, the rate of competitive release does not contribute to the DAPC
weighting (−0.02).
An aggressive strategy is more likely to minimize resistance when the DR strain is relatively unfit
(low R02), and the DR population is supported by a high rate of acquisition. Furthermore, an
aggressive strategy is likely to be best when the strains are more independent (a low similarity
coefficient). Independence means that even a relatively unfit strain can be transmitted in the
population, despite the presence of a more fit strain, because when strains are independent they can
each super-infect hosts already infected with the other strain, and they can be transmitted from those
with dual infection (if these cannot happen then the strains cannot be independent; rather, they would
compete for hosts and/or for infectivity). We noted previously (Colijn et al., 2009) that such co-
infection can, but does not always, allow DR strains to persist in the long term where they would not
be able to do so otherwise; similar results were recently reported by Hansen and Day (2014). Our
current results clarify that these effects are a result of the level of competition and are not a
consequence of co-infection. Co-infection can be present under high, low, or intermediate levels of
competition.
The factors that favor an aggressive policy—lower R02, higher rates of resistance acquisition and
increased independence between strains—have the net impact of reducing inter-strain competition. A
low R01 also makes an aggressive approach more likely to be preferred (see Appendix figure 9);
competition for hosts is low when there are plenty of susceptible hosts, whether the model has strict
competition mechanisms or not. This occurs when both R0 values are low. Low R02 means the DR strain
is not a fit competitor, a high independence (1 − c) explicitly reduces competition through protection
from re-infection and through independent recovery, and a higher mutation rate increases the benefit
the DR strain enjoys from DS.
We used the same approach to quantify the short-term competitive interaction as in the within-host
model. We reduced the population of the sensitive strain, iterated the model forward two time steps,
and computed the effect on the resistant strain (in the absence of treatment). We used the average
proportional change in the resistance strain following this direct reduction in the sensitive strain to
predict what would happen (increase or decrease) to resistance under treatment. As in the within-host
model, this measure of effective competition is a good predictor of the effect of treatment (AUC 0.94;
Appendix figure 10).
The models are directly linked through the competitive release, r, which reflects a portion (in the
between-host model) of treated sensitive infections that convert to resistant ones. Even where this
does not occur at all (r = 0), successful treatment of individuals drives population-level resistance when
strains are competing. Consider the within-host model in the regime where aggressive treatment
minimizes resistance, for example, low DR growth Λr or a strong immune system, or high rate of
acquisition of resistance. Individuals treated successfully are not susceptible to, or infectious with, the
sensitive strain. At the between-host level, though, they may remain susceptible to a circulating
resistant strain, which now has more susceptible hosts available than the sensitive strain. Treatment
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(reducing R01) moves the system to the left on the invasion plot (Figure 5C), increasing resistance if
there is effective competition at the between-host level.
Discussion
An aggressive policy for antibiotic treatment is preferred when the appearance and persistence of DR
is driven by the existence of a sufficiently large DS population. In these settings, the benefits to the DR
population which accrue from the acquisition of resistance from DS outweigh the costs of competition
from a larger DS population. In contrast, a moderate dosing policy is preferred when the DR strain is a
fit enough competitor that acquisition of resistance plays a sufficiently small role in the DR population
dynamics. Here, the cost of competition from the DS population outweighs the benefit of additional
DR bacteria appearing through acquired resistance. Both modes occur in models containing
acquisition of resistance and competition, and a small change in parameters can shift models from one
mode to the other. Understanding why previous models and theory have differed in support of
aggressive (Ehrlich, 1913; Knudsen et al., 2003;Wiuff et al., 2003; Tam et al., 2005; D’Agata et al.,
2007; Ankomah and Levin, 2014; Kim et al., 2014) and moderate (de Roode et al., 2004; Wargo
et al., 2007; Gullberg et al., 2011; Huijben et al., 2013) approaches requires evaluating both
structural assumptions and parameter choices (Spicknall et al., 2013) as these together affect the
strength of effective competition between DR and DS strains. We have used a comprehensive
approach to exploring these assumptions and have begun the process of defining measures of
effective competition to predict whether moderate or aggressive treatment minimizes resistance.
Previous contradictory results on this question fit neatly into the framework we have presented. In
Ankomah and Levin (2014), the model structure incorporates complex interactions between strains,
allowing for many facets of competition to be explored. At their chosen parameter values, however,
there is little effective competition between DR and DS strains and they found an aggressive policy to
be best. In a recent work by Kim et al. (2014), DR strains had two alleles with no onward fitness
evolution, little in-host competition, and low DR fitness; consequently, they also found that an
aggressive approach would be best. Another recent model (Gomes et al., 2013) assumed that there
was competition for resources at high bacterial populations, and concluded that this competition
could play a role in suppression of resistant strains. Work by Geli et al. (2012) explored different
ecological dynamics and found that strong immunity supports an aggressive policy, but that selection
was most intensive at intermediate strengths of treatment in chronic infections (Geli et al., 2012;
Kouyos et al., 2014). Gullberg et al. (2011) found that even low concentrations of antibiotic (where
the DR and DS fitness may not differ) can rapidly enrich DR sub-populations. Huijben et al. (2013)
found experimentally that competitive release of (pre-existing and relatively fit) resistant strains
increased with increasing drug pressure.
We conclude that both of these perspectives are reasonable. We find that even in a system where
aggressive approaches are most frequently best (the within-host model, based on Ankomah and
Levin (2014)), a moderate approach can be preferred if the DR strain is slightly more fit and the
environment is slightly more permissive; in this case, inter-strain competition mechanisms, which are
always present, are more effective. Likewise, at the between-host level where we might expect herd-
level competition effects to play out, we find that even where competition mechanisms are strong, an
aggressive approach may be best of one or both strains have a low basic reproduction number or if
the rate of acquisition of resistance is high. Both of these factors limit the effective competition.
In most circumstances, we expect that DR and DS variants of a single pathogen compete quite
strongly: they will be closely related, and so are likely to share antigenic properties and induce a
similar host immune response. They are also likely to consume or be reliant on similar host resources
(Fiegna and Velicer, 2005) and occupy similar biological niches within hosts (Dall’Antonia et al.,
2005; Lam and Monack, 2014). The extent to which these aspects dominate the fact that resistance is
also driven by de novo acquisition, and hence benefits from high DS population levels, will depend on
the acquisition rate and mechanism (Lipsitch and Samore, 2002) as well as on the degree of effective
competition. Furthermore, models have typically reflected competition for host resources or via a
carrying capacity (Geli et al., 2012; Gomes et al., 2013; Ankomah and Levin, 2014), such that
competition takes place at high bacterial populations. If direct antagonistic (Claverys and Ha˚varstein,
2007; Baquero and Lemonnier, 2009) or cooperative (Diard et al., 2013) interactions occur, they are
likely to substantially alter the extent and timing of competition, with profound onward consequences
for optimal treatment.
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We do want to emphasize some key differences between the problem of minimizing resistance
among each individual receiving treatment and minimizing resistance of circulating pathogens in a
community (Lipsitch et al., 2000; Lipsitch and Samore, 2002; Cohen et al., 2006; zur Wiesch et al.,
2011; Geli et al., 2012; Mills et al., 2013). Consider, for example, an immune-competent individual
initially harboring a drug-susceptible infection free of any (or many) sporadically resistant isolates. An
aggressive approach may well be preferred for this individual. However, if there is a fit resistant strain
circulating in the community, then this policy can drive substantial resistance at the population level
(e.g., by selectively suppressing the DS strain, making hosts susceptible to re-infections only with the
DR strain), even if it does not increase the risk of acquiring resistance in any individual given treatment.
Consequently, an aggressive approach might well be best at the individual level while still driving
resistance over longer time frames. An aggressive approach may also diminish in utility over time if DR
strains become fitter through selection, if they begin to circulate widely and compete with DS strains
(zur Wiesch et al., 2011).
Co-infection of individual hosts by multiple strains or isolates has been observed for most
pathogens in which it has been investigated (Balmer and Tanner, 2011), and we have incorporated it
in both models. At the population level, models that fail to include co-infection assume that co-
infections do not occur; this equates to a very strong assumption about competition for hosts,
regardless of whether there is sufficient data to inform co-infection parameters.
We have previously argued that diversity-promoting mechanisms in models should be explicit
(Lipsitch et al., 2009) and that ‘neutral’ models are a useful framework for understanding implicit
assumptions in multi-strain models. Here, we note that such neutrality is competition. The ‘no
coexistence for free’ directive can be reframed: we expect identical strains to compete. The extent of
competition is a key driver of how the balance between multiple strains changes in response to
interventions; if we are to use models to understand these responses, we must be clear about the
mechanisms and the extent of effective competition between strains.
These results highlight the importance of identifying empirical data that reveal whether effective
competition between DS and DR strains is present. Experimental approaches in which mixed bacterial
populations are studied in vitro or in vivo may reveal mechanisms by which these sub-populations may
exhibit interference competition through direct interaction (Claverys and Ha˚varstein, 2007) or
exploitative competition through shared dependence on a common resource (Fiegna and Velicer,
2005). These types of controlled experiments have been valuable for identifying conditions under
which such direct competition effects are likely to manifest within individual hosts. Identifying data
that would reveal the conditions under which we would expect competition between DS and DR
strains at the community level is clearly more challenging. The scale and the timing at which we would
expect to observe the effects of intraspecific competition will likely differ by pathogen type. Similar to
studies of vaccines or other interventions in which indirect effects are important to consider,
community-randomized trials are the most promising design, but the expense and logistics of such
trials for considering different antibiotic dosing strategies may be prohibitive.
In the absence of such trials, relating population-level antibiotic use data to surveillance data
describing trends in resistance in the community may help to identify signals of such competition.
Detailed analysis of the numbers and ages of treated cases, the population density, ‘drug-bug’
interactions, and the time since resistance first emerged (Turnidge and Christiansen, 2005) could
improve our ability to do this. Meanwhile, careful consideration of the level of effective competition is
essential when using models to understand the relationship between antimicrobial use and resistance.
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Appendix 1
Between-host model: two ends of a continuum
Here, we compare a model with two very different, independent pathogens circulating in a
community, and the 2-strain neutral null model (Lipsitch et al., 2009). Previously (Lipsitch
et al., 2009; Colijn et al., 2010), we argued that neutrality is required in order for a model of
multiple strains to make biological sense when the strains are identical: in this case, it should
not matter which strain an individual or sub-group is infected with. The dynamics of the total
prevalence should depend only on the numbers of hosts infected. Furthermore, each strain
should have the same ability to cause new infections and should not be comparatively
advantaged or disadvantaged by being rare. Otherwise, an arbitrary re-labeling of some cases
(all of whom have identical strains by assumption) alters which of these cases seed new
infections.
These two conditions constrain the equations of any multi-strain model. First, if dual infection
can result from re-infection, then re-infection must also be able to out-compete one of the
strains in a dually infected host, leading back to single infection. Otherwise, dual infection can
protect a rare strain (Lipsitch et al., 2009; Colijn et al., 2010), as was also noted recently in
Hansen and Day (2014). Second, in the limit in which the infections are identical, recovery from
one and not the other is not logical; dually infected hosts recover back to susceptible. Finally,
dually infected hosts contribute the same total infectiousness to the force of infection, divided
equally between the strains (This assumption can be relaxed while preserving neutrality, but
doing so requires also modeling hosts with multiple single infections [Lipsitch et al., 2009].).
We found (Lipsitch et al., 2009; Colijn et al., 2010) that models that reduce to this neutral
interaction when strains are identical also do not promote coexistence of diverse strains.
Here, we have developed a model that incorporates this neutral null limit when the strains are
very similar, but which also allows the possibility that strains are very different, to the point of
not interacting with each other at all. Different strains might inhabit very different niches within
hosts, trigger different immune responses, act over different time periods, be transmitted
through different routes, and so on. When strains are independent, new infection events do not
displace existing strains, but add to them. Hosts clear strains independently, so that when a
dually infected host recovers from one strain, they remain (singly) infected with the other.
Finally, dually infected hosts are equally infectious with each strain as they would be if they
didn’t have the other strain. These requirements also constrain the equations of a model
representing the two strains.
We have developed a model that captures these very different limiting interactions and allows
us to explore the continuum between them.
A (SIS, or susceptible-infected-susceptible) model with two entirely independent strains must
look something like this:
dS
dt
=B−FxS−FyS− uS+ uxX + uyY
dX
dt
=FxS−FyX + uyD− uxX
dY
dt
=FyS−FxY + uxD− uyY
dD
dt
=FyX +FxY − uxD− uyD;
(3)
with Fx = βx(X + D), Fy = βy(Y + D) and B a birth term.
For independence, we require that the total prevalence of each strain evolves as it would
without the other strain. For example, the total prevalence of X is Tx = X + D and the number
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susceptible to strain X is Sx = Y + S = 1 − Tx. Adding the second and fourth equations of
Equation 3, we have
d
dt
ðX +DÞ= βxðX +DÞðS+YÞ− uxðX +DÞ;
which is
dTx
dt
= βxTxSx − uxTx;
namely exactly the single-strain SIS model. We have the analogous expression for Y. Solving
these de-coupled equations for Tx and Ty is equivalent to solving Equation 3, so Equation 3
describes independent dynamics. Furthermore, Equation 2 reduces to Equation 3 when the
similarity coefficient c is 0 (and T = 0).
When the strains are very similar (c = 1), Equation 2 in the main text reduces to Equation 14 of
Lipsitch et al. (2009) with (their) c = q = 1/2. That model was shown to be neutral through its
equivalence with Equation 1 in the same work. This is the origin of the terms in Equation 2 with
1
2 c in them; when our similarity coefficient is 1, these terms become the relevant terms in
Lipsitch’s model (14) for (their) c = 1/2.
The models differ in their re-infection from the dual class (0 where the similarity coefficient is 0)
and in the clearance terms from the dually infected hosts. To obtain those clearance terms in
Equation 2, we interpolate: We have three potential clearance terms: (1) dual to X, (2) dual to Y,
and (3) dual to S (not shown in Equation 2 because S = 1 − X − Y − D). When c = 0, these terms
need to be uxD, uyD, and 0, respectively. When c = 1, they need to be 0, 0 and 12 ðux + uyÞD,
where the latter means that when the strains are identical the clearance is correct. Interpolating
(with terms (1), (2), (3) in vector notation), we have these three terms as
ð1− cÞ× ðuxD; uyD; 0Þ+ c×

0; 0; 12 ðux + uyÞD

. This yields the model in Equation 2.
We note that the result of this interpolation is related to recent work on coinfection (Hansen
and Day, 2014), in which the authors ask how co-infection may drive increase in resistance
(through an increased ability Rr of the DR strain to invade a DS-strain’s equilibrium, in the
dynamical sense). They find that co-infection can increase Rr more when the DR strain is more
productive within co-infections (has a higher contribution to the force of infection), and when it
has a higher ability to co-infect the DS strain. Our results are consistent with this, but our
framing points out that these effects occur because of how these aspects of co-infection modify
the net competition between the strains.
We verified numerically that the model has independent SIS dynamics for each strain when
c = 0. We also verified that when c = 1, T = 0 and the parameters for the two strains are
identical, the model is neutral in the sense of Lipsitch et al. (2009). When the parameters are
not identical but c = 1, the model exhibits competitive exclusion.
When c = 0, the two infections do not interact with each other—each spreads as it would
without the other one present. A hypothetical example might be pneumococcal carriage and
human papillomavirus (HPV). They likely do not have much immune response in common, and
both can be asymptomatic and would likely not affect each other’s transmission. They have very
low similarity. This is at one end of a spectrum, and modellers do not choose to model
transmission of these infections simultaneously (precisely because they would not affect each
other). However, low values of c are implicitly assumed by models (of the same infection with
different strains, e.g., resistant and sensitive) that do not take competition into account, for
example, by including co-infection in a way that dramatically reduces competition (see also the
discussion in Nicoli et al. (2015)).
The final model in (2) contains, in the first equation of (2), terms for: entry from susceptibles into
X (FxS), re-infection of X with the Y strain (κFyX), re-entry to X from duals re-infected with
X

1
2
κtcFxD

, clearance of X (uxX), clearance of the Y strain in duals (1 − c)uyD, and acquisition
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of resistance plus competitive release of resistance due to treatment (μ + Tr)X. The second
equation is analagous and the third, for duals, describes their infection, re-infection back to
singly infected states and clearance.
Implementation
Models were implemented in Matlab and solved with ode15s, which is a built-in ODE solver in
Matlab capable of handling stiff systems. Stiffness was an issue in the within-host model
because of the wide range of orders of magnitude of both the variables (with cell numbers
reaching 1010) and the parameters, together with the sharp threshold on the DR growth at Br =
30. This was used to model the possibility of stochastic die-off of low populations of DR, and
incidentally also prevents growth from only a fraction of a cell, which would otherwise be
possible when using a continuous model to approximate a discrete variable. Parameters were
generated uniformly over the ranges shown, except for μ in the within-host model. There, log10
(μ) was uniformly distributed, to explore lower mutation rates more deeply than higher ones.
The parameter ranges for the within-host model all surround the values used in Ankomah and
Levin (2014). Stratified bar plots and color density plots were created in ggplot2 in R. The
smoothing and density estimation analysis for Figures 4, 7 and Appendix figure 1 was done
with the stat_density2d function in ggplot2.
Colijn and Cohen. eLife 2015;4:e10559. DOI: 10.7554/eLife.10559 20 of 29
Research article Epidemiology and global health | Microbiology and infectious disease
Appendix figure 1. Heatmaps illustrating whether aggressive therapy (yellow), moderate therapy (blue) or
neither, conclusively (neutral; green) minimize resistance. (Top set of panels) Pre-existing resistance means
that the ‘moderate is best’ conclusion is spread out more widely over the parameter space; the DR strain
does not benefit as much from DS growth. (Bottom set of panels) Without pre-existing resistance, there is
more clear separation between the parameter regimes. Overall, the results are the same as in the main text:
a moderate outcome is driven by high effective competition between strains, meaning a higher ΛR, mR and
lower values of immune parameters kp and η (eta).
DOI: 10.7554/eLife.10559.011
Sensitivity analysis
We performed single-parameter sensitivity analyses in both models. These demonstrate that
most parameters, varied on their own over the permissive ranges we have used in the overall
parameter exploration, do not typically move the system from the mode in which treatment
decreases resistance to the mode where resistance increases (competition). Appendix figures 2, 3
illustrate single-parameter variation in the in-host model, and Appendix figure 4 illustrates it in the
between-host model. Appendix figure 5 illustrates that in the majority of cases there is a strong
correlation between treatment strength and resistance, whether negative or positive.
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Appendix figure 2. Sensitivity analysis, varying one parameter at a time. For each value of each parameter,
the dosage was increased from 0 to 2.5 μg/ml per day, and the maximum number of DR bacilli during the
infection was recorded. The baseline values of the parameters (when they were not varied) are: Λs = 0.5,
Λr = 0.45, mR = 2.8 and the remainder are as in Table 1.
DOI: 10.7554/eLife.10559.012
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Appendix figure 3. Sensitivity analysis, varying one parameter at a time. For each value of each parameter,
the dosage was increased from LOW to HIGH, and the maximum number of DR bacilli during the infection
was recorded. The baseline values of the parameters (when they were not varied) are: Λs = 0.6, Λr = 0.53,
mR = 3.4. Other parameters are k = 48, kp = 2.2e−6, ki = 7.2e−4, μ = 4e−7, α = 0.018, σi = 1000, σp = 10000,
γp = 0.001 and the rest as in Table 1. The approach is the same as that in Appendix figure 2, except that
the baseline set of parameters is different.
DOI: 10.7554/eLife.10559.013
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Appendix figure 4. Sensitivity analysis, varying one parameter at a time in the between-host model
over the ranges listed in Table 1. Left side: baseline parameter values are βx = 1.5, βy = 1.04, c = 0.05, r = 0,
μ = 0.001. Right side: baseline values are βx = 2, βy = 1.1, c = 0.3, r = 0.05, μ = 0.0001.
DOI: 10.7554/eLife.10559.014
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Appendix figure 5. Spearman correlations between treatment level and maximum resistance in both
models. (Left) In-host model. Left panel shows all parameters. Right panel shows only those for which
treatment succeeds. The difference is that where treatment does not succeed, it drives resistance.
(Right) Population-level model.
DOI: 10.7554/eLife.10559.015
How parameter combinations affect the treatment–resistance
relationship
In the in-host model, whether a DR strain needs to emerge only after treatment begins, during a
rise in bacterial burden in the DS strain, affects the inter-strain dynamics, because pre-existing
resistance reduces the positive impact of the DS strain on the DR strain. We repeated the
analysis underlying Figure 4, using only the subset with pre-existing resistance, and then only
those results without pre-existing resistance. Other parameters ranged over the same intervals.
Discriminant analysis of principle components (Jombart et al., 2010) (DAPC) finds
combinations of variables that best separate groups (here, whether treatment increases or
decreases resistance, or ‘neutral’). DAPC results indicated that almost all of the difference
between the groups can be accounted for using a single discriminant function, both in the
within-host model and the between-host one. Appendix figure 6 shows the groups plotted on
the first two discriminant axes, illustrating the separation of the groups. The horizontal axis is
the first discriminant function whose higher coefficients are given in the main text.
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Appendix figure 6. DAPC scatterplot for the within-host model. The x-axis is a linear combination of
parameters corresponding to the primary DAPC discriminant function, and the y-axis corresponds to the
second. Accordingly, the groups are plotted by their positions on the first two DAPC axes. The relative
portions of the variance that these axes capture is illustrated in the DACP eigenvalue plot (bottom right
corner). Almost all of the difference between the groups is captured by the x-axis (high gray bar in the
bottom left plot, compared to a low gray bar for the variation captured by the second axis). The PCA
eigenvalues plot in the bottom right shows the portion of variance retained when keeping k PCA axes. In
both models, the neutral group, in which treatment was not strongly correlated with the level of resistance
in either direction, lies directly between the aggressive and moderate groups.
DOI: 10.7554/eLife.10559.016
Appendix figures 7, 8 show the parameters of the in-host model, selected according to
whether an aggressive or a moderate treatment approach is best to minimize resistance. In the
top rows, the aggressive policy is preferred (treatment decreases resistance); we see a lower
MIC of the DR strain (labeled mR), a stronger immune system (higher kp and η (eta)), a lower Λr
and also lower Λs. The lower Λs results in fewer DS bacilli, so fewer DR bacilli are created
through mutation, allowing an aggressive policy to prevent their emergence.
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Appendix figure 7. Parameters from the two regimes: (a) with the lysis term and (b) without it. In each set,
the top row shows the parameters under which resistance decreases with increasing dosage, and the
bottom row shows those for which resistance increases with increasing dosage. The relationships between
the two outcomes (treatment increasing or decreasing resistance) are unaffected by whether the lysis term is
included. Removing the term is akin to including lysis in the equation for the resource usage, but with an e
coefficient of 0; a more general model could include this with a coefficient el < e which would model the fact
that resource consumption and release could happen with different efficiencies. Though we do not know
what an appropriate choice for el would be, the results with el = 0 (bottom set of histograms) are the same
as those with el = e (original model; top set of histograms).
DOI: 10.7554/eLife.10559.017
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Appendix figure 8. Parameters in the two modes showing that the filter defining ‘effective treatment’ does not
change the relationships between parameters and whether treatment increases or decreases resistance. We have
shown only the parameters whose distributions are different in the two modes (compare to Appendix figure 7).
DOI: 10.7554/eLife.10559.018
Appendix figure 9 shows the histograms and scatter plots for the between host model. These
illustrate the same points made in the main text but again show the relationships between the
parameters that were varied. An aggressive policy is most likely best when the DR strain has a
relatively low basic reproductive number R02, and when the similarity coefficient is low. A low
similarity coefficient means that competition is reduced, because the extent to which the strains
are interacting is lower than when strains are very similar. Finally, Appendix figure 10 shows
that the measure of effective competition defined in the main text can predict the relationship
between treatment and resistance, in both the within- and between- host models.
Appendix figure 9. Parameters where the two contrasting policies work best in the population level model.
Top row: treatment decreases resistance. Bottom row: treatment increases resistance.
DOI: 10.7554/eLife.10559.019
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Appendix figure 10. Quality of classification using the instantaneous measure of effective competition to
classify a parameter set according to whether treatment will increase or decrease resistance. A random
classifier has an AUC of 0.5. We used the sign of the Spearman correlation between treatment and
resistance as the ‘true’ classification (competing if treatment increases resistance), and the value of our
effective competition quantity as the ‘scores’. Curves were created using the perfcurve function in matlab.
DOI: 10.7554/eLife.10559.020
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